Articles dans des revues avec comité de lecture (47)
  1. 1. Collet, L., Ardin, M., Venet, D., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Noel, J.-C., Leheurteur, M., Meunier, J., Bengrine Lefevre, L., Martinez, M., Priou, F., Selle, F., Just, P. A., Bataillon, G., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial. Clinical cancer research. doi:10.1158/1078-0432.CCR-24-2712
  2. 2. Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-1007
  3. 3. Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-3
  4. 4. Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w
  5. 5. Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., & Sotiriou, C. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open, 9(5), 102964. doi:10.1016/j.esmoop.2024.102964
  6. 6. Fernandez-Martinez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K. K., Venet, D., Rashid, N. N., Spears, P. P., Islam, M. N., El-abed, S., Bliss, J. M., Lambertini, M. M. P. M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. P., Swain, S. S., Sotiriou, C., Perou, C. C., & Carey, L. L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA oncology. doi:10.1001/jamaoncol.2023.7304
  7. 7. Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J. M., Bonnefoi, H., Canon, J.-L., Duhoux, F. P., Mansi, L., Poncin, R., Barthélémy, P., Isambert, N., Denis, Z., Catteau, X., Salgado, R., Agostinetto, E., de Azambuja, E., Rothé, F., Craciun, L., Venet, D., Romano, E., Stagg, J., Paesmans, M., Larsimont, D., Sotiriou, C., Ignatiadis, M., & Piccart-Gebhart, M. (2023). Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications, 14(1), 7018. doi:10.1038/s41467-023-42744-y
  8. 8. Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
  9. 9. Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-1267
  10. 10. Lengrand, J., Pastushenko, I., Vanuytven, S., Song, Y., Venet, D., Sarate, R. M., Bellina, M., Moers, V., Boinet, A., Sifrim, A., Rama, N., Ducarouge, B., Van Herck, J., Dubois, C., Scozzaro, S., Lemaire, S., Gieskes, S., Bonni, S., Collin, A., Braissand, N., Allard, J., Zindy, E., Decaestecker, C., Sotiriou, C., Salmon, I., Mehlen, P., Voet, T., Bernet, A., & Blanpain, C. (2023). Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature (London). doi:10.1038/s41586-023-06372-2
  11. 11. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  12. 12. Cailleux, F., Agostinetto, E., Lambertini, M., Rothé, F., Wu, H.-T., Balcioglu, M., Kalashnikova, E., Vincent, D., Viglietti, G., Gombos, A., Papagiannis, A., Veys, I., Awada, A., Sethi, H., Aleshin, A., Larsimont, D., Sotiriou, C., Venet, D., & Ignatiadis, M. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology, 6, e2200148. doi:10.1200/PO.22.00148
    13. << Précédent 1 2 3 4 5 Suivant >>